2269:HKG
WuXi Biologics (Cayman) Inc
48,20 HKD
arrow_downward
−0,90%(−0,44) 1D
16. lis, 16:08:14 GMT+8 · HKD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za 2269...
Otvori
49,98 HKD
Najviša
50,85 HKD
Najniža
45,82 HKD
Trž. kap.
198,43 mlr.
Prosj. kol.
30,42 mil.
Količina
55,18 mil.
P/E omjer
34,48
52-tjed. najviša
58,00 HKD
52-tjed. najniža
28,48 HKD
EPS
1,40 HKD
Dionice u optjecaju
1,23 mlr.
Broj djelatnika
15 tis.
Otvori
49,98 HKD
Najviša
50,85 HKD
Najniža
45,82 HKD
Trž. kap.
198,43 mlr.
Prosj. kol.
30,42 mil.
Količina
55,18 mil.
P/E omjer
34,48
52-tjed. najviša
58,00 HKD
52-tjed. najniža
28,48 HKD
EPS
1,40 HKD
Dionice u optjecaju
1,23 mlr.
Broj djelatnika
15 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Financije.hr
·
prije 1 dan
Wall Street pred otvaranjem: Rotacija iz tehnologije jača, Dow preuzima vodstvo
CryptoRank
·
prije 1 sat
Ripple and XRP Weekly Wrap: Institutional Wins, Nasdaq Debut, and Price Struggles
MarketBeat
·
prije 47 minuta
Wynn Resorts, Limited (NASDAQ:WYNN) Stock Has Average Price Target of $130.12 According to Brokerages
The Globe and Mail
·
prije 2 sata
Sandisk Is Dominating the S&P 500 in 2026. Can It Repeat in 2027?
Profil
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development.
WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017.
As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore.
In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong.
In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
WuXi Biologics (Cayman) Inc – informacije
Glavni izvršni direktorZhisheng Chen
Zaposlenici14,7 tis.
Osnovano2010
Sjedište-
Sektor-
Web-lokacijawuxibiologics.com